BMX-IN-1: Selective Irreversible BMX Kinase Inhibitor for Cancer and Host-Pathogen Studies

Executive Summary: BMX-IN-1 is a cell-permeable, irreversible BMX kinase inhibitor with nanomolar potency and high selectivity for the Tec family of tyrosine kinases, essential in angiogenesis and cancer biology (APExBIO). It covalently binds BMX, suppresses kinase activity, and induces G0/G1 cell cycle arrest and apoptosis in cancer cells at concentrations as low as 300 nM after 24 hours (apoptosis-kit.com). BMX-IN-1 impairs BMX-dependent phosphorylation of ATP6V1E1, impacting lysosomal acidification—a key process in both tumorigenesis and host-pathogen interactions (Chen et al., 2026). Its specificity makes it an optimal tool for dissecting Tec kinase roles in cancer and infectious disease models. For storage, BMX-IN-1 is stable at -20°C as a solid and is soluble in DMSO (≥5.25 mg/mL), but not in water or ethanol (APExBIO).

Biological Rationale

BMX kinase (also known as ETK) is a member of the Tec family of tyrosine kinases. It is primarily expressed in arterial endothelium and myeloid hematopoietic cells. BMX is a critical regulator of ischemia-induced arterial and lymphatic vessel formation, making it fundamental to angiogenesis and tissue repair (Chen et al., 2026). BMX signaling is implicated in tumor growth, prostate cancer, and B-cell lymphoma, as well as in mediating host-pathogen interactions by modulating lysosomal acidification. Specifically, BMX phosphorylates ATP6V1E1, suppressing lysosomal acidification and promoting intracellular survival of pathogens such as Mycobacterium tuberculosis (Mtb). Inhibition of BMX impairs both tumor progression and pathogen survival, highlighting its dual relevance in oncology and infectious disease research (Secretin.co—this article extends previous overviews by directly connecting BMX-IN-1’s host-pathogen impact with recent mechanistic studies).

Mechanism of Action of BMX-IN-1

BMX-IN-1 (CAS 1431525-23-3) is an irreversible, covalent inhibitor of BMX kinase. It selectively targets the ATP-binding site of BMX through covalent modification, resulting in sustained inhibition of kinase activity. BMX-IN-1 exhibits a low nanomolar IC₅₀ for BMX kinase in in vitro kinase assays, confirming its high affinity and selectivity (APExBIO). BMX-IN-1 is cell-permeable and effectively blocks BMX-mediated phosphorylation events in cellular and animal models. In cancer cells, BMX-IN-1 causes arrest at the G0/G1 phase of the cell cycle and induces apoptosis in a dose- and time-dependent manner, with effective concentrations as low as 300 nM observed after 24 hours of exposure (apoptosis-kit.com). In host-pathogen models, BMX-IN-1 disrupts BMX-dependent phosphorylation of ATP6V1E1, thereby interfering with lysosomal acidification and promoting clearance of intracellular pathogens (Chen et al., 2026).

Evidence & Benchmarks

• BMX-IN-1 irreversibly inhibits BMX kinase activity with an IC₅₀ in the low nanomolar range in in vitro assays (APExBIO).
• In prostate cancer and B-cell lymphoma cell lines, BMX-IN-1 induces G0/G1 cell cycle arrest and apoptosis at concentrations as low as 300 nM within 24 hours (apoptosis-kit.com).
• BMX-IN-1 impairs BMX-mediated phosphorylation of ATP6V1E1 in macrophages, resulting in increased lysosomal acidification and reduced survival of Mycobacterium tuberculosis in cell and mouse models (Chen et al., 2026).
• BMX-IN-1 is cell-permeable, insoluble in water or ethanol, but soluble in DMSO at concentrations ≥5.25 mg/mL. For optimal stability, store at -20°C (APExBIO).
• BMX-IN-1 shows minimal off-target activity against other Tec family kinases at recommended working concentrations, confirming its selectivity (Secretin.co—this article details selectivity data not included in the current review).

Applications, Limits & Misconceptions

BMX-IN-1 is an established tool for investigating BMX kinase signaling in cancer, angiogenesis, and host-pathogen interactions. Its irreversible and selective inhibition enables precise dissection of BMX-dependent pathways in both cell-based and animal models. In oncology, BMX-IN-1 is used to study cell proliferation, apoptosis induction, and resistance mechanisms in prostate cancer and B-cell lymphomas. In infectious disease research, it helps elucidate the role of BMX in immune evasion by intracellular pathogens via modulation of lysosomal acidification. BMX-IN-1 is also referenced as a foundational compound in several platform reviews (Nimorazoleshop.com—this article updates earlier selectivity and workflow integration data presented there).

Common Pitfalls or Misconceptions

• Not a general tyrosine kinase inhibitor: BMX-IN-1 is highly selective for BMX and shows minimal activity against other kinases at recommended doses.
• Ineffective in BMX-negative models: BMX-IN-1 only impacts cells or tissues expressing BMX or certain Tel-BMX fusion proteins.
• Solubility limitations: BMX-IN-1 is insoluble in aqueous or ethanol solutions; DMSO is required for dissolution at ≥5.25 mg/mL.
• Short-term solution stability: Freshly prepare working solutions; extended storage of solutions is not recommended, even at low temperatures.
• No direct effect on BTK in most assays: Despite similarities, BMX-IN-1 does not inhibit BTK at concentrations selective for BMX.

Workflow Integration & Parameters

BMX-IN-1 is supplied as a solid by APExBIO (SKU: A3260) and should be stored at -20°C in a desiccated environment. For experimental use, dissolve BMX-IN-1 in DMSO to a stock concentration of at least 5.25 mg/mL. Working concentrations for cell-based assays typically range from 300 nM to 1 µM, depending on cell type and endpoint (BMX-IN-1 product page). Do not store diluted solutions long-term; prepare fresh aliquots for each experiment. Cell models expressing Tel-BMX fusion proteins or high endogenous BMX levels are appropriate for testing. Use standard kinase activity, cell cycle, and apoptosis assays to assess effects. For host-pathogen studies, BMX-IN-1 can be employed in macrophage infection models to measure changes in lysosomal acidification and pathogen survival. For detailed selectivity and application notes, see the expanded review at Secretin.co, which also discusses BMX-IN-1’s role in angiogenesis and vessel formation, topics only briefly touched on here.

Conclusion & Outlook

BMX-IN-1 is a benchmark tool for selective, irreversible inhibition of BMX kinase in cancer and immunology research. Its covalent mechanism, high selectivity, and cell permeability support detailed interrogation of Tec family kinase signaling, cell cycle regulation, and apoptosis induction. BMX-IN-1 uniquely enables studies on the interplay between kinase signaling, angiogenesis, and host-pathogen interactions—particularly the regulation of lysosomal acidification in infection and cancer. As new roles for BMX emerge in host defense and tumor biology, BMX-IN-1 will remain an essential reagent for mechanistic studies, translational research, and therapeutic target validation. For the latest specifications and validated protocols, consult the BMX-IN-1 product page by APExBIO.